Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Ocular Therapeutix, Inc

NASDAQ: OCUL · Life Sciences · 8 alerts · CIK 1393434

Share price
$6.01Close, Nov 16
Market cap
$1.32B
Shares outstanding
220.02MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Ocular Therapeutix, Inc filings on SEC EDGAR ↗

7:19 AM ET 10-Q
Financial Results

Ocular Therapeutix Q3 2026 Results: Net Loss of $94.8M, Loss Widens

Ocular Therapeutix reported a decrease in cash and cash equivalents to $530.6 million as of September 30, 2026, compared to $737.1 million at year-end 2025. Total assets decreased to $605.6 million, while total liabilities increased slightly to $164.7 million. The company is currently focused on Phase 3 clinical trials for AXPAXLI in wet AMD and NPDR.

Key figure
Net loss $94.8M
7:09 AM ET 8-K
Financial Results

Ocular Therapeutix Financial Results

Ocular Therapeutix reported Q3 2026 financial results, highlighting a cash position of $530.6 million and an expected runway into 2028. The company remains on track to submit its NDA for AXPAXLI in wet AMD during Q4 2026 following a positive pre-NDA meeting with the FDA in September.

Term
Q3 2026

“2026 has been a transformational year for Ocular Therapeutix and we are in a strong position as we prepare to submit our NDA for AXPAXLI in wet AMD under the 505(b)(2) regulatory pathway. Frequent injections define today’s wet AMD treatment experience, and we believe AXPAXLI has the transformative potential to drastically reduce the burden on patients and caregivers.”

Pravin U. Dugel, MD, Executive Chairman, President and CEO of Ocular Therapeutix

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.